1. THE 'NEW' DRUG CLASSES IN THE TREATMENT OF CHRONIC HEART FAILURE AND THEIR EVIDENCE BASE
- Author
-
S. N. Tereshchenko, I. V. Zhirov, A. G. Kochetov, and O. V. Uspenskaya
- Subjects
хроническая сердечная недостаточность ,рандомизированное клиническое исследование ,ивабрадин ,омега-3 полиненасыщенные жирные кислоты ,Therapeutics. Pharmacology ,RM1-950 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
A comparison of ivabradine and omega-3 polyunsaturated fatty acids, drugs with principally different mechanisms of action, is presented in patients with chronic heart failure (CHF) on the base of GISSI-HF and SHIFT trails results. It is essential to compaire an effect of these drugs on the morbidity and mortality in combined therapy of patients with CHF , because each additional drug may change in compliance to treatment, induces additional costs or may be a reason of new side effects. Additional (to standard therapy) effects of ivabradine and omega-3 polyunsaturated fatty acids are discussed.
- Published
- 2015
- Full Text
- View/download PDF